• Gastric cancer, also known as stomach cancer, is the fourth most common cancer worldwide with approximately 1,000,000 cases diagnosed annually
• Recently, REC8 has been identified to play a key role on the epigenetic alteration and biological function during the development of gastric cancer
• To develop a sensitive and convenient quantification test of our identified methylated DNA marker REC8 for non-invasive diagnosis and prognosis of gastric cancer

• Novel gastric cancer biomarker identified by us
• New molecular test which quantitates levels of methylated and unmethylated alleles of REC8 in a specimen at the same time, no need of internal control
• Better diagnostic performance than currently available molecular diagnosis of gastric cancer
• Good performance in prognostic prediction for patients with gastric patients

• Clinically ready
• Advantage: Highly sensitive, specific, and convenient to be performed

Reduced REC8 expression in plasma for non-invasive diagnosis of gastric cancer.

High methylation level of REC8 significantly correlates with shortened survival in patients with gastric cancer

Molecular Diagnostics

P-2018-0857

CN201810481334.3 HK19124760.0 US2020/0024668 A1

Yu J. et al, Oncogene, 2017 

Zhao J. et al, Cancer, 2013

orkts.liaison@cuhk.edu.hk